Lactobacillus rhamnosus GKLC1 ameliorates cisplatin-induced chronic nephrotoxicity by inhibiting cell inflammation and apoptosis

You-Shan Tsai; Yen-Po Chen; Shih-Wei Lin; Yen-Lien Chen; Chin-Chu Chen; Guan-Jhong Huang

Biomedicine & Pharmacotherapy (Mar 2022)

Lactobacillus rhamnosus GKLC1 ameliorates cisplatin-induced chronic nephrotoxicity by inhibiting cell inflammation and apoptosis

You-Shan Tsai,
Yen-Po Chen,
Shih-Wei Lin,
Yen-Lien Chen,
Chin-Chu Chen,
Guan-Jhong Huang

Affiliations

You-Shan Tsai: Biotech Research Institute, Grape King Bio Ltd., Taoyuan City 325002, Taiwan
Yen-Po Chen: Biotech Research Institute, Grape King Bio Ltd., Taoyuan City 325002, Taiwan
Shih-Wei Lin: Department of Food Science and Biotechnology, National Chung Hsing University, Taichung City 402204, Taiwan
Yen-Lien Chen: Biotech Research Institute, Grape King Bio Ltd., Taoyuan City 325002, Taiwan
Chin-Chu Chen: Institute of Food Science and Technology, National Taiwan University, Taipei City 106319, Taiwan; Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei City 104336, Taiwan; Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan; Corresponding author at: Institute of Food Science and Technology, National Taiwan University, Taipei City 106319, Taiwan.
Guan-Jhong Huang: Department of Chinese Pharmaceutical Science and Chinese Medicine Recourses, College of Chinese Medicine, China Medical University, Taichung City 40402, Taiwan; Department of Health and Nutrition Biotechnology, Asia University, Taichung City 413305, Taiwan; Corresponding author at: Department of Chinese Pharmaceutical Science and Chinese Medicine Recourses, College of Chinese Medicine, China Medical University, Taichung City 40402, Taiwan.

Journal volume & issue: Vol. 147
p. 112701

Abstract

Read online

Sustained usage of the chemotherapeutic drug cisplatin may lead to chronic kidney disease (CKD). Despite cisplatin being toxic to the kidneys, the efficiency of its therapeutic effects cannot be completely replaced with other drugs. Probiotics can produce various strain-specific health-promoting effects and suppress many specific diseases. In this study, we present the alleviation of cisplatin-induced CKD with a probiotic, Lactobacillus rhamnosus GKLC1. Intermittent low doses of cisplatin were given to male CB57BL/6 mice (n = 6), which induced CKD symptoms such as weight loss, lesions in kidney tissue, and increases in blood urea nitrogen (BUN) and creatinine (CRE) in serum. The rats received two weeks of L. rhamnosus GKLC1 orally at doses of 125, 250, and 500 mg/kg B.W./day. After the treatment, significant dose-dependent reductions were observed in the kidney index, histopathological scoring, serum BUN, and CRE. An LLC-PK1 kidney cell assay revealed that L. rhamnosus GKLC1 suppressed the nephrotoxicity of cisplatin by reducing the inflammation via the MAPKs/NF-ĸB/COX-2 pathway, inhibiting apoptosis via the p53/Bax/Caspase-3 pathway, and ameliorating fibrosis via the STAT3 pathway. We conclude that L. rhamnosus GKLC1 could be applied as an agent to ameliorate the development of CKD.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords